Latest news

Nanologica AB (publ) today May 21, 2026 held its Annual General Meeting in Stockholm, at which the following resolutions were adopted.   Adoption of the income statement and balance sheet, disposition of result The Annual General Meeting adopted the income statement and balance sheet for the company and the group in accordance with the presented accounting documents and resolved, in accordance with the board’s proposal, that the accumulated loss of SEK -50,180,846 shall be carried

FINANCIAL SUMMARY Net sales for the first quarter amounted to SEK 21,456 thousand (10,751). Operating profit for the quarter amounted to SEK 66,484 thousand (-9,241). Operating profit is affected by the fact that the acquisition of Syntagon is recorded as an operating income of SEK 78 876 thousand during the period. Profit before tax for the quarter amounted to SEK 65,186 thousand (-10,171) Earnings per share before and after dilution were SEK 0.72 (-0.14) for the

Syntagon AB, a subsidiary of Nanologica AB (publ), has recruited Alexandra Pichard Nielsen to the newly established role of Vice President Business Development. The recruitment is part of the strategy to increase focus on sales and business development with the goal of increasing Syntagon’s sales. In January 2026, Nanologica acquired Ardena Södertälje AB, which is now run as a subsidiary within the Nanologica Group under the name Syntagon. Nanologica believes that Syntagon has good opportunities

The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the “Company“) are hereby summoned to the Annual General Meeting on Thursday 21 May 2026, at 10.00 CET, at Advokatfirman Lindahl’s premises at Smålandsgatan 16, Stockholm. Right to attend the meeting Shareholders who wish to participate in the Annual General Meeting must: be registered in their own name in the share register maintained by Euroclear Sweden AB on Wednesday 12 May 2026, notify the Company of its

Nanologica has received an order of appx. SEK 2 million for the company’s silica-based purification media NLAB Saga®. The customer is a manufacturer of peptide drugs, and the order relates to evaluation of NLAB Saga® on a production scale. Nanologica’s team has been working with this customer for a few years, including carrying out an extensive application development project for them. With this order, the customer will proceed to evaluate NLAB Saga® on a production